Cinclus Pharma presented at ABGSC investor days
Cinclus Pharma's CEO, Christer Ahlberg, presented Cinclus Pharma at the ABGCS seminar on November 22-23.
Read more
In the spotlight
Check out the latest updates from Cinclus Pharma
Cinclus Pharma announces positive FDA interaction
Cinclus Pharma today announces that the company has completed a successful so-called end-of-phase-II meeting, with the US Food and Drug Administration (FDA) for the indication erosive gastroesophageal reflux disease (eGERD). The FDA broadly accepted Cinclus Pharma's proposal for the phase III program, including study design and primary endpoint for the studies. The positive outcome allows Cinclus Pharma to proceed with its phase III program.
Read more
Lennart Hansson, visionary and experienced Chairman of the Board
Cinclus Pharma's co-founder and Chairman of the Board, Lennart Hansson, has long experience from leading positions at various biotech and pharmaceutical companies. He has also worked at AstraZeneca on gastrointestinal diseases and has served on more than 30 company boards. At Cinclus Pharma, all this experience is now put to good use.
Read more